



OPEN ACCESS

## EXTENDED REPORT

# Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids

Jun Won Park,<sup>1</sup> Jeffrey R Curtis,<sup>2</sup> Jinyoung Moon,<sup>1</sup> Yeong Wook Song,<sup>1</sup> Suhnggwon Kim,<sup>3,4</sup> Eun Bong Lee<sup>1</sup>

Handling editor Tore K Kvien

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2017-211796>).

<sup>1</sup>Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea  
<sup>2</sup>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA  
<sup>3</sup>Division of Nephrology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea  
<sup>4</sup>Seoul Kidney Clinic, Seoul, Republic of Korea

## Correspondence to

Dr Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea; [leb7616@snu.ac.kr](mailto:leb7616@snu.ac.kr)

Received 15 May 2017  
 Revised 1 October 2017  
 Accepted 22 October 2017  
 Published Online First 1 November 2017



► <http://dx.doi.org/10.1136/annrheumdis-2017-212588>



**To cite:** Park JW, Curtis JR, Moon J, et al. *Ann Rheum Dis* 2018;**77**:644–649.

## ABSTRACT

**Objectives** To investigate the efficacy and safety of trimethoprim/sulfamethoxazole (TMP-SMX) as primary prophylaxis for pneumocystis pneumonia (PCP) in patients with rheumatic diseases receiving high-dose steroids.

**Methods** The study included 1522 treatment episodes with prolonged ( $\geq 4$  weeks) high-dose ( $\geq 30$  mg/day prednisone) steroids in 1092 patients over a 12-year period. Of these, 262 treatment episodes involved TMP-SMX (prophylaxis group) while other episodes involved no prophylaxis (control group). Differences in 1-year PCP incidence and its mortality between the two groups were estimated using Cox regression. To minimise baseline imbalance, propensity score matching was performed and efficacy outcome was mainly assessed in the postmatched population (n=235 in both groups).

**Results** During a total of 1474.4 person-years, 30 PCP cases occurred with a mortality rate of 36.7%. One non-fatal case occurred in the prophylaxis group. TMP-SMX significantly reduced the 1-year PCP incidence (adjusted HR=0.07(95% CI 0.01 to 0.53)) and related mortality (adjusted HR=0.08 (95% CI 0.0006 to 0.71)) in the postmatched population. The result of the same analysis performed in the whole population was consistent with that of the primary analysis. Incidence rate of adverse drug reactions (ADR) related to TMP-SMX was 21.2 (14.8–29.3)/100 person-years. Only two serious ADRs (including one Stevens-Johnson syndrome case) occurred. The number needed to treat for preventing one PCP (52 (33–124)) was lower than the number needed to harm for serious ADR (131 (55–∞)).

**Conclusion** TMP-SMX prophylaxis significantly reduces the PCP incidence with a favourable safety profile in patients with rheumatic disease receiving prolonged, high-dose steroids.

## INTRODUCTION

Pneumocystis pneumonia (PCP) caused by *Pneumocystis jirovecii* is a common but potentially life-threatening infection in immunocompromised patients.<sup>1</sup> Although it had been the most common cause of death in patients infected by HIV, the advent of effective HIV treatment and prophylactic strategy led to marked fall of its incidence.<sup>2</sup> However, it remains a significant cause of pneumonia in non-HIV immunocompromised patients. In addition, PCP in non-HIV patients usually shows

more severe manifestations and carries a higher mortality rate than that in HIV-infected patients.<sup>3–5</sup>

The most important risk factor for PCP in non-HIV patients is the use of immunosuppressive drugs, especially corticosteroids. Prolonged treatment with high-dose steroids is a significant risk factor for PCP in patients with haematologic malignancies, solid organ transplants and rheumatic diseases.<sup>4 6 7</sup> Thus, current guidelines recommend PCP prophylaxis for patients receiving immunosuppressive drugs, including steroids.<sup>8</sup> However, there is no consensus on PCP prophylaxis for patients with rheumatic diseases because the absolute incidence of PCP in this group is unclear<sup>9</sup> and no risk-benefit assessment for prophylactic regimen has been performed. Thus, this has led to different opinions among rheumatologists regarding PCP prophylaxis.<sup>10</sup>

To find the answers to these problems, we examined the incidence of PCP in patients diagnosed with a rheumatic disease and receiving prolonged high-dose steroid treatment. Patients were recruited from a large tertiary referral centre over a 12-year period. In addition, we evaluated the efficacy and safety of PCP prophylaxis to enable a useful risk-benefit assessment.

## METHODS

### Patients and clinical data

The electronic medical database at Seoul National University Hospital was examined, and patients with a rheumatic disease treated with high-dose steroid for more than 4 consecutive weeks (defined as a treatment episode) between January 2004 and December 2015 were identified. High-dose steroid was defined as  $\geq 30$  mg/day prednisone or equivalent, as suggested by Buttgerit *et al.*<sup>11</sup> The ICD-10 (International Classification of Diseases, 10th Revision) codes used for case identification are presented in online supplementary text. Patients with a history of PCP, HIV infection, current cancer, or a solid organ transplant, or those less than 18 years of age were excluded. Next, all treatment episodes were classified into two groups (control group vs prophylaxis group) according to whether a patient receiving high-dose steroid had started primary PCP prophylaxis.

The baseline date was defined as the first day of PCP prophylaxis (prophylaxis group) or high-dose

steroid (control group). Each patient should maintain high-dose steroid for at least 4 weeks from the baseline date. The observation period for each treatment episode was 1 year from the baseline date because previous studies suggest that most PCP cases occur within this period.<sup>4 12 13</sup> Therefore, prolonged high-dose steroid treatment which started within the last 1 year from the baseline date in the prophylaxis group could not be entered into the observation period of the control group. But if a patient restarted prolonged high-dose steroid treatment after more than 1 year from the baseline date, it was counted as a separate treatment episode. The primary outcome was the incidence of PCP in each group during the observation. Secondary outcomes included PCP-related mortality and incidence of adverse drug reactions (ADR) related to PCP prophylaxis. All suspected ADRs were reviewed and assigned a probability of causation based on the timing and known patterns of adverse effects. Probable/likely or certain causality was regarded as an ADR.<sup>14</sup>

Patient consent was waived by the IRB due to the retrospective nature of the study.

### Detection of PCP during treatment episodes

A complex algorithm (see online supplementary figure S1) was used to capture all PCP cases during the observation. Briefly, data from confirmatory microbiologic tests such as PCR and direct fluorescent antibody staining of induced-sputum or bronchoalveolar lavage fluid were collected. The medical records of patients with positive results and fulfilling the criteria for analysis were then reviewed to ascertain whether they showed features consistent with PCP, such as fever or acute dyspnea, along with characteristic radiographic findings. A positive PCR result in the absence of clinical manifestations was not considered as PCP.

### PCP prophylaxis

Trimethoprim/sulfamethoxazole (TMP-SMX) was the only agent used for PCP prophylaxis in this study and was given as one double-strength tablet three times a week or as one single-strength tablet per day. Selection of patients for PCP prophylaxis and its duration were mainly determined by the treating physician. TMP-SMX was started on the first day of high-dose steroid treatment in most cases (unless contraindicated) and was stopped when the daily steroid dose (based on prednisone) was tapered: to 30 mg in 35 (13.6%) treatment episodes, 25 mg in 6 (2.3%), 20 mg in 26 (10.1%), 15 mg in 53 (20.6%) and <15 mg/day in 113 (44.0%). For patients with renal insufficiency, the TMP-SMX dose was adjusted accordingly (determined by creatinine clearance, n=23). Second-line antibiotics against PCP such as dapsone, atovaquone or aerosolised pentamidine were not used for primary prophylaxis against PCP during the observation period.

### Statistical analysis

Continuous or dichotomous baseline data were compared using Student's t-test or the  $\chi^2$  test as appropriate. Cox proportional hazards regression models were used to estimate the effect of TMP-SMX on outcome. The HR was adjusted for baseline clinical factors that showed a significant association ( $P<0.1$ ) with outcome. In addition, the final model was adjusted for intra-cluster correlation as some patients may have undergone multiple treatment episodes. With respect to PCP-related mortality, which showed the complete separation of outcome, Firth's penalised maximum likelihood was used to reduce statistical bias.<sup>15</sup>

Since there were differences between the groups in terms of baseline characteristics, the same survival analyses were

undertaken after applying 1:1 propensity score (PS) matching. This was carried out using the patients' age, cumulative steroid dose during the 6 months prior to baseline, concomitant use of immunosuppressants (cyclophosphamide and steroid pulse), lymphopenia ( $<800/\mu\text{L}$ ) and the presence of certain underlying diseases as predictors of a requirement for prophylaxis; the selected calliper was 0.2. After matching, 235 treatment episodes from each group were selected for use as the postmatched populations (see online supplementary figure S2). Although a comparison of PCP incidence and related mortality was performed before and after matching, primary outcome was mainly assessed in the postmatched population because it was expected to have less statistical bias regarding the number of covariates per case. All statistical analyses were performed using R V3.3.1 software, and a P value  $<0.05$  was considered statistically significant.

## RESULTS

### Patient characteristics

A total of 1522 treatment episodes from 1092 patients were fulfilled the criteria for analysis. TMP-SMX prophylaxis was performed in 262 treatment episodes, with a mean (SD) duration of 237.0 (272.2) days. Patients received daily single-strength TMP-SMX regimen in most treatment episodes (251/262, 95.8%). Prophylaxis began on the first day of high-dose steroid treatment (except in nine cases in which TMP-SMX prophylaxis was delayed by more than 1 month from the initiation of high-dose steroid due to acute kidney injury (n=4), leucopenia (n=3) or pregnancy (n=2)).

The baseline characteristics of the control and prophylaxis groups are shown in table 1. Patients in the prophylaxis group were older, more likely to have lymphopenia and to be treated with secondary immunosuppressive agents. In addition, the proportion of patients with diseases associated with a high risk of PCP, such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and dermatomyositis, was significantly higher in the prophylaxis group. The cumulative steroid dose administered during the entire observation period was also higher in the prophylaxis group (based on prednisone,  $7158\pm 4552$  mg vs  $8202\pm 5145$  mg,  $P=0.001$ ). There were no significant differences in the above-mentioned clinical factors in the postmatched population (table 2).

### Incidence of PCP

During the observation period of 1474.4 person-years, there were 30 PCP cases in 30 patients: the incidence rate (95% CI) in the control group was 2.37 (1.59–3.41)/100 person-years. When the whole population was stratified according to underlying disease, the incidence of PCP was highest in those with GPA and MPA (12.14 (95% CI 3.94 to 28.33) per 100 person-years), followed by those with systemic sclerosis (10.88 (95% CI 2.24 to 31.80) per 100 person-years), dermatomyositis (3.11 (95% CI 0.64 to 9.07) per 100 person-years) and systemic lupus erythematosus (SLE) (2.42 (95% CI 1.36 to 4.00) per 100 person-years). The mean time interval between baseline and PCP was 3.4 (SD=2.5, min=0.9, max=10.8) months and 27 (90.0%) cases occurred within the first 6 months. The mean (SD) dose of steroid (based on prednisone) at the time of PCP diagnosis was 31.3 (SD=20.1, min=5, max=80) mg; 15 (50%) cases occurred when the dose was  $\geq 30$  mg/day, 12 cases when 15–30 mg/day and 3 cases when  $<15$  mg/day. Twenty-nine cases of PCP developed in the control group, whereas only one case occurred in the prophylaxis group. However, in this case, TMP-SMX was discontinued prematurely due to ADR. Among all PCP cases,

**Table 1** Baseline\* characteristics of the whole population

(n=number of treatment episodes)	Control group (n=1260)	Prophylaxis group (n=262)	P value
Male gender, n (%)	374 (29.7)	89 (34.0)	0.170
Age, year, mean (SD)	41.2 (15.2)	46.2 (16.0)	<0.001
Disease duration, year, mean (SD)	3.0 (3.8)	2.5 (4.0)	0.053
Underlying disease			
Systemic lupus erythematosus, n (%)	636 (50.5)	122 (46.8)	0.249
Systemic sclerosis, n (%)†	30 (2.4)	5 (1.9)	0.642
Dermatomyositis, n (%)	100 (7.9)	38 (14.5)	0.001
Polymyositis, n (%)	54 (4.3)	12 (4.6)	0.831
GPA, n (%)	38 (3.0)	18 (6.9)	0.003
MPA, n (%)	9 (0.7)	11 (4.2)	<0.001
EGPA, n (%)	43 (3.4)	7 (2.7)	0.541
Polyarteritis nodosa, n (%)	17 (1.3)	7 (2.7)	0.118
Rheumatoid arthritis, n (%)‡	58 (4.6)	10 (3.8)	0.575
Adult-onset Still's disease, n (%)	31 (2.5)	9 (3.4)	0.369
Behcet's disease, n (%)	182 (14.4)	12 (4.6)	<0.001
Cryoglobulinaemic vasculitis, n (%)	1 (0.1)	2 (0.8)	0.023
Ankylosing spondylitis, n (%)	12 (1.0)	0 (0.0)	0.113
Primary Sjogren's syndrome, n (%)	3 (0.2)	0 (0.0)	0.429
Others, n (%)‡	47 (3.7)	9 (3.4)	0.817
Initial steroid dose of 30–45 mg PD, n (%)	426 (33.8)	88 (33.6)	0.945
Initial steroid dose of 45–60 mg PD, n (%)	141 (11.2)	42 (16.0)	0.028
Initial steroid dose of ≥60 mg PD, n (%)	696 (55.0)	132 (50.4)	0.172
Concomitant immunosuppressive treatment			
Steroid pulse treatment, n (%)	164 (13.0)	99 (37.8)	<0.001
Oral cyclophosphamide, n (%)	49 (3.9)	34 (13.0)	<0.001
Cyclophosphamide pulse treatment, n (%)	99 (7.9)	67 (25.6)	<0.001
Cumulative steroid dose, mean (SD)§	1597.1 (1568.7)	3119.7 (1821.5)	<0.001
Lymphopenia, n (%)¶	283 (22.5)	87 (33.2)	<0.001

\*The baseline date was defined as the day on which PCP prophylaxis (prophylaxis group) or high-dose steroid (control group) was started.  
 †The main reason for the use of high-dose steroids in these diseases was associated interstitial lung disease.  
 ‡Including Takayasu's arteritis, temporal arteritis and relapsing polychondritis.  
 §Cumulative steroid (prednisone) dose during the previous 6 months.  
 ¶Defined as <800 lymphocytes/mL.  
 EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; PD, prednisone.

16 (53.3%) received mechanical ventilation and 11 (36.7%) expired. All PCP-related deaths occurred in the control group. Clinical features of PCP cases at baseline and PCP occurrence are summarised in online supplementary tables S1 and S2, respectively.

The incidence of PCP tended to increase according to the increase in the initial steroid dose. Patients receiving ≥60 mg/day prednisone showed a significantly higher PCP incidence than those in other subgroups (figure 1).

### Efficacy of TMP-SMX prophylaxis in the PS-matched population


Univariable analysis in the PS-matched population revealed that the 1-year incidence of PCP significantly decreased with

**Table 2** Baseline\* characteristics of the PS-matched population

(n=number of treatment episodes)	Control group (n=235)	Prophylaxis group (n=235)	P value
Male gender, n (%)	173 (73.6)	161 (68.5)	0.222
Age, year, mean (SD)	45.8 (16.3)	45.5 (15.7)	0.843
Disease duration, year, mean (SD)	3.1 (4.0)	2.6 (3.9)	0.200
Underlying disease			
Systemic lupus erythematosus, n (%)	109 (46.4)	112 (47.7)	0.782
Systemic sclerosis, n (%)†	6 (2.6)	5 (2.1)	0.760
Dermatomyositis, n (%)	34 (14.5)	34 (14.5)	1.000
Polymyositis, n (%)	17 (7.2)	10 (4.3)	0.165
GPA, n (%)	16 (6.8)	13 (5.5)	0.565
MPA, n (%)	8 (3.4)	8 (3.4)	1.000
EGPA, n (%)	6 (2.6)	7 (3.0)	0.779
Polyarteritis nodosa, n (%)	7 (3.0)	6 (2.6)	0.779
Rheumatoid arthritis, n (%)‡	9 (3.8)	9 (3.8)	1.000
Adult-onset Still's disease, n (%)	2 (0.9)	8 (3.4)	0.106
Behcet's disease, n (%)	11 (4.7)	12 (5.1)	0.831
Cryoglobulinaemic vasculitis, n (%)	1 (0.4)	2 (0.9)	0.562
Ankylosing spondylitis, n (%)	3 (1.3)	0 (0.0)	0.248
Primary Sjogren's syndrome, n (%)	1 (0.4)	0 (0.0)	0.317
Others, n (%)‡	5 (2.1)	9 (3.8)	0.278
Initial steroid dose of 30–45 mg PD, n (%)	70 (29.5)	72 (30.9)	0.747
Initial steroid dose of 45–60 mg PD, n (%)	29 (12.2)	39 (16.7)	0.165
Initial steroid dose of ≥60 mg PD, n (%)	138 (58.2)	122 (52.4)	0.201
Concomitant immunosuppressive treatment			
Steroid pulse treatment, n (%)	84 (35.7)	80 (34.0)	0.699
Oral cyclophosphamide, n (%)	20 (8.5)	25 (10.6)	0.433
Cyclophosphamide pulse treatment, n (%)	54 (23.0)	54 (23.0)	1.000
Cumulative steroid dose, mean (SD)§	2696.6 (2123.1)	2898.6 (1558.8)	0.240
Lymphopenia, n (%)¶	73 (31.1)	76 (32.3)	0.766

\*The baseline date was defined as the day on which PCP prophylaxis (prophylaxis group) or high-dose steroid (control group) was started.  
 †The main reason for the use of high-dose steroids in these diseases was associated interstitial lung disease.  
 ‡Including Takayasu's arteritis, temporal arteritis and relapsing polychondritis.  
 §Cumulative steroid (prednisone) dose during the previous 6 months.  
 ¶Defined as <800 lymphocytes/mL.  
 EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; PD, prednisone; PS, propensity score.

prophylaxis (HR=0.07; 95% CI 0.01 to 0.54). This result was also consistent with the result of multivariable analysis including age and MPA as covariates (adjusted HR=0.07; 95% CI 0.01 to 0.53). PCP-related mortality in the prophylaxis group fell significantly in both univariable analysis (HR=0.07, 95% profile likelihood CI 0.0005 to 0.55) and multivariable analysis (adjusted HR=0.08; 95% profile likelihood CI 0.0006 to 0.71) (table 3). The HR and its significance level for other covariates are presented in online supplementary table S3.



**Figure 1** Kaplan-Meier curve showing pneumocystis pneumonia (PCP)-free survival according to the initial dose of steroids (30-45 mg/day prednisone, 45-60 mg/day and ≥60 mg/day) in the whole population. PD, prednisone.

Since the incidence of PCP increased according to the increase in the initial steroid dose, we next examined the efficacy of TMP-SMX prophylaxis after stratifying all treatment episodes by this factor. In the subgroup with a higher initial steroid dose (≥60 mg/day prednisone) (n=261), TMP-SMX led to a significant reduction in PCP incidence after adjusting for GPA (adjusted HR=0.05; 95% profile likelihood CI 0.0004 to 0.40). However, the effectiveness was not

apparent in the subgroup receiving a lower initial steroid dose (HR=0.36; 95% profile likelihood CI 0.04 to 2.21).

**Efficacy of TMP-SMX prophylaxis in the whole population**

In the whole population, the 1-year incidence of PCP tended to decrease with prophylaxis (HR=0.17; 95% CI 0.02 to 1.22). MPA, higher steroid dose, concomitant cyclophosphamide pulse and baseline lymphopenia were associated with an increased incidence of PCP (see online supplementary table S4). After adjusting for these factors, the prophylaxis group showed a significantly lower incidence of PCP than control group (HR=0.06; 95% CI 0.004 to 0.66) (table 4). As in the PS-matched population, TMP-SMX significantly reduced PCP incidence only in the subgroup with a higher initial steroid dose (n=825) (adjusted HR=0.02; 95% profile likelihood CI 0.0001 to 0.24).

TMP-SMX was also associated with a reduction in PCP-related mortality after adjusting for age, GPA, MPA and concomitant steroid pulse treatment (adjusted HR=0.09; 95% profile likelihood CI 0.0007 to 0.76) (table 4).

**ADRs associated with prophylactic TMP-SMX**

During the 170.1 person-year duration of TMP-SMX prophylaxis, 36 ADRs (of any type) occurred in 32 patients (21.2/100 person-years; 95% CI 14.8 to 29.3). The most common ADRs were elevated (>1.5 the upper normal range) serum alanine transaminase levels and a skin rash (3.5/100 person-years for both), followed by thrombocytopenia (1.8/100 person-years) and hyperkalaemia

**Table 3** Effect of TMP-SMX prophylaxis on 1-year PCP incidence and related mortality in the propensity score-matched population (n=470)

	1-year PCP incidence		1-year PCP-related mortality*	
	HR (95% CI)		HR (95% profile likelihood CI)	
	Univariable analysis	Multivariable analysis†	Univariable analysis	Multivariable analysis‡
TMP-SMX prophylaxis	0.07 (0.01 to 0.54)	0.07 (0.01 to 0.53)	0.07 (0.0005 to 0.55)	0.08 (0.0006 to 0.71)
P value for HR	0.010	0.010	0.007	0.019

\*Firth's penalised maximum likelihood was used due to complete separation of outcome.

†Included age and MPA as covariates, and was also adjusted for clustering.

‡Included age, GPA and MPA as covariates, and was also adjusted for clustering. GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.

**Table 4** Effect of TMP-SMX prophylaxis on 1-year PCP incidence and related mortality in the whole population (n=1522)

	1-year PCP incidence		1-year PCP-related mortality*	
	HR (95% CI)		HR (95% profile likelihood CI)	
	Univariable analysis	Multivariable analysis†	Univariable analysis	Multivariable analysis‡
TMP-SMX prophylaxis	0.17 (0.02 to 1.22)	0.06 (0.004 to 0.66)	0.21 (0.002 to 1.61)	0.09 (0.0007 to 0.76)
P value for HR	0.078	0.022	0.165	0.023

\*Firth's penalised maximum likelihood was used due to complete separation of outcome.

†Included age, MPA, initial steroid dose ( $\geq 60$  mg/day prednisone vs not), concomitant cyclophosphamide pulse and baseline lymphopenia as covariates, and was also adjusted for clustering.

‡Included age, GPA, MPA and concomitant steroid pulse as covariates, and was also adjusted for clustering.

GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.

(1.8/100 person-years) (table 5). There were no lupus flares during prophylaxis. In most cases, ADR severity was mild to moderate (34/36, 94.4%). There were only two cases of serious ADRs that led to prolonged hospitalisation (one case of pancytopenia and one case of Stevens-Johnson syndrome) (1.2/100 person-years, 95% CI 0.1 to 4.2). However, they resolved shortly after discontinuation of TMP-SMX.

### Risk-benefit analysis of TMP-SMX prophylaxis

Based on the two cases of serious ADR, the number needed to harm (NNH) was 131 (55– $\infty$ ). By contrast, the number needed to treat (NNT) to prevent one case of PCP in the whole population was 52 (33–124). After stratification according to each underlying disease, the NNT in patients with SLE (43 (28–85)) or MPA (3 (1.6–39.4)) was lower than the NNH. The same was true for other diseases; however, the 95% CI for absolute risk reduction extended

**Table 5** Incidence of adverse drug reactions caused by trimethoprim/sulfamethoxazole prophylaxis

	Number of cases*	Incidence rate (95% CI)†
Adverse drug reactions	34	20.6 (14.3 to 28.6)
Anaemia	2	1.2 (0.1 to 4.2)
Leucopenia	1	0.6 (0.0 to 3.3)
Thrombocytopenia	3	1.8 (0.4 to 5.2)
GI problems	2	1.2 (0.1 to 4.2)
LFT abnormality	6	3.5 (1.3 to 7.7)
Skin rash	6	3.5 (1.3 to 7.7)
Azotaemia	5	3.0 (1.0 to 7.1)
Hyperkalaemia	3	1.8 (0.4 to 5.2)
Others‡	6	3.5 (1.3 to 7.7)
Serious adverse drug reactions	2	1.2 (0.1 to 4.2)
Pancytopenia	1	0.6 (0.0 to 3.3)
Stevens-Johnson syndrome	1	0.6 (0.0 to 3.3)

\*Total observation period was 170.1 person-years for 262 cases.

†Rate per 100 person-years.

‡Including headache (1), anorexia (1), eosinophilia (1), tingling sensation (1) and pruritus (2).

GI, gastrointestinal; LFT, liver function test.

from a negative number to a positive number, making it irrelevant. Interestingly, when we stratified treatment episodes according to initial steroid dose ( $\geq 60$  mg/day prednisone vs other), the NNT for the subgroup receiving a higher steroid dose was 32 (22–54), whereas that for the subgroup receiving a lower steroid dose was 215 (45– $\infty$ ), which is higher than the NNH for serious ADRs.

### Sensitivity analysis

Because differences in the dosing regimens of TMP-SMX could have influenced its efficacy, we performed the same Cox regressions after excluding subgroups with atypical TMP-SMX dosing, including (1) twenty-three treatment episodes with a renal dose adjustment, (2) ten with a thrice weekly TMP-SMX regimen and (3) nine with more than a month's delay in prophylaxis. The result from each of these analyses was consistent with the original one (data not shown).

Since patients in the prophylaxis group discontinued TMP-SMX at various times, we analysed the data using a censoring scheme based on tapering of steroids (eg, 30 mg/day and 15 mg/day prednisone). The prophylactic effect of TMP-SMX was unchanged (see online supplementary figure S3). In addition, to minimise the effect of heterogeneity in the duration of prophylaxis, we also performed the same analysis using 6 and 3-month observation periods, respectively. Using these censoring schemes, the mean (SD) proportion of time that TMP-SMX was administered was significantly increased (0.50 (0.33) in the original analysis vs 0.70 (0.32) and 0.86 (0.25) in 6-month and 3-month time frames, respectively,  $P < 0.001$ ). However, the efficacy of prophylaxis was unaffected by the change in observation period (see online supplementary figure S4).

### DISCUSSION

Systemic high-dose steroid treatment is one of the most important weapons against rheumatic diseases; however, it is a risk factor for PCP. Many studies describe an association between PCP and steroid use in patients with rheumatic disease, but few have investigated the prophylactic effects in such populations.<sup>16–18</sup> To the best of our knowledge, this is the largest study conducted to investigate the efficacy and safety of TMP-SMX prophylaxis in patients with rheumatic diseases who received prolonged high-dose steroids. The incidence of PCP in the control group was 2.37/100 person-years, which is consistent with previous reports.<sup>19</sup>

TMP-SMX was highly effective at preventing PCP and related mortality. In contrast, compared with that reported in other studies of HIV-positive patients, TMP-SMX showed a lower incidence of ADRs.<sup>20</sup> Recent meta-analyses on the efficacy of PCP prophylaxis in patients with haematologic malignancy or post-transplantation suggest that TMP-SMX should be considered when the NNT is balanced against the NNH for severe ADRs.<sup>21 22</sup> Overall, the NNT herein was 52, whereas that for severe ADRs was 131, illustrating that the benefit of TMP-SMX prophylaxis was greater than the risk of potential harm to the patient. Interestingly, in the subgroup that received a higher initial steroid dose, the NNT was even lower. This demonstrates that, in patients receiving  $\geq 60$  mg/day prednisone, the benefits of TMP-SMX prophylaxis outweigh the risks. This result suggests that initial steroid dose may identify patients who would derive maximum benefit from TMP-SMX prophylaxis.

The optimal time to stop PCP prophylaxis in non-HIV patients receiving high-dose steroids remains unclear. Expert opinion suggests that prophylaxis should be continued until the CD4 T cell count rises above  $200/\text{mm}^3$  for 6 consecutive months.<sup>23</sup> However, the correlation between this factor and the risk for PCP is less clear in patients without HIV.<sup>24</sup> In that context, it is noteworthy that most PCP cases (90.0%) in the present study occurred when

a patient received  $\geq 15$  mg/day prednisone or equivalent, which is in line with the findings of previous studies.<sup>13 18 24 25</sup> This suggests that tapering the dose of steroid down to  $< 15$  mg/day might be a relevant point at which to consider stopping prophylaxis. In agreement with previous reports, we found that PCP showed a significant association with concomitant cyclophosphamide, lymphopenia and old age, and at least one of these risk factors was present in all instances of PCP in patients receiving  $< 15$  mg/day prednisone.<sup>13 23 26</sup> However, because of the small number of PCP cases, it should be precautionous to define relevant time point of stopping prophylaxis with this result alone.

This study has some limitations. First, the baseline characteristics of the prophylaxis and non-prophylaxis groups were not fully balanced, a limitation inherent to observational studies. To overcome this limitation, primary analysis was performed based on PS-matching population; however, unmeasured confounders such as physician's preference cannot be completely balanced without randomisation. Second, the number of PCP cases in this study was rather small so we could not perform a precise risk-benefit assessment for some rheumatic diseases. In addition, because this was not a randomised controlled study, we could not compare the prevalence of adverse events between the two groups; therefore, the NNH was based on the ADR from the prophylaxis group alone.

In conclusion, we show here the benefit of TMP-SMX as primary prophylaxis for PCP in patients with rheumatic diseases who were treated with prolonged high-dose steroids; this was particularly true for patients receiving an initial steroid dose  $\geq 60$  mg/day prednisone or equivalent. Although the results should be confirmed in a future randomised study, the data may impact the use of PCP prophylaxis for patients with rheumatic diseases.

**Contributors** EBL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: EBL, JRC, SK and JWP. Acquisition, analysis or interpretation of data: JWP, JRC, JM, YWS and EBL. Drafting of the manuscript: EBL, JRC and JWP. Critical revision of the manuscript for important intellectual content: JWP, JRC, JM, YWS, SK and EBL. Statistical analysis: EBL, JRC and JWP.

**Funding** This research was partly supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1A02937044).

**Competing interests** EBL has acted as a consultant to Pfizer, and received research grants from Green Cross Corp and Hanmi Pharm Company. The other authors declare no conflicts of interest.

**Patient consent** Informed consents were waived based on the retrospective nature of the study.

**Ethics approval** The study was approved by the Institutional Review Board of the Seoul National University Hospital (IRB 1508-050-694) and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

- 1 Thomas CF, Limper AH. Pneumocystis pneumonia. *N Engl J Med* 2004;350:2487–98.
- 2 Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. *Emerg Infect Dis* 2004;10:1713–20.
- 3 Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. *Chest* 2000;118:704–11.
- 4 Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc* 1996;71:5–13.
- 5 Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. *Clin Infect Dis* 2002;34:1098–107.
- 6 Maeda T, Babazono A, Nishi T, et al. Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia. *Br J Haematol* 2015;168:501–6.
- 7 Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. *Am J Transplant* 2013;13(Suppl 4):272–9.
- 8 Limper AH, Knox KS, Sarosi GA, et al. An official american thoracic society statement: Treatment of fungal infections in adult pulmonary and critical care patients. *Am J Respir Crit Care Med* 2011;183:96–128.
- 9 Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. *J Rheumatol* 1994;21:246–51.
- 10 Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis. *J Rheumatol* 2010;37:792–9.
- 11 Buttgerit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. *Ann Rheum Dis* 2002;61:718–22.
- 12 Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. *Nephrol Dial Transplant* 2011;26:2013–7.
- 13 Lertnawapan R, Totemchokchayakarn K, Nantiruj K, et al. Risk factors of Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus. *Rheumatol Int* 2009;29:491–6.
- 14 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356:1255–9.
- 15 Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Stat Med* 2002;21:2409–19.
- 16 Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. *Semin Arthritis Rheum* 2011;41:497–502.
- 17 Ogawa J, Harigai M, Nagasaka K, et al. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. *Mod Rheumatol* 2005;15:91–6.
- 18 Chew LC, Maceda-Galang LM, Tan YK, et al. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. *J Clin Rheumatol* 2015;21:72–5.
- 19 Roux A, Gonzalez F, Roux M, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. *Med Mal Infect* 2014;44:185–98.
- 20 Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. *Clin Microbiol Rev* 2004;17:770–82.
- 21 Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2007;82:1052–9.
- 22 Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. *The Cochrane database of systematic reviews* 2014;01:CD005590.
- 23 Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. *Arthritis Rheum* 2008;59:1034–9.
- 24 Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002–2004. *Scand J Infect Dis* 2007;39(6–7):589–95.
- 25 Roblot F, Le Moal G, Kauffmann-Lacroix C, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. *Scand J Infect Dis* 2014;46:210–4.
- 26 Teichtahl AJ, Morrisroe K, Cicciello S, et al. Pneumocystis jirovecii pneumonia in connective tissue diseases: Comparison with other immunocompromised patients. *Semin Arthritis Rheum* 2015;45:86–90.